Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1Phase 1 1

Status

Completed 15Terminated 3

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Gastrointestinal Neoplasms 1Carcinoma, Hepatocellular 1Advanced Hepatocellular Carcinoma (HCC) 1

Interventions

pembrolizumab 184Carboplatin 130Paclitaxel 123Gemcitabine 122Docetaxel 96Cyclophosphamide 89Nivolumab 88Cisplatin 87Rituximab 71Dexamethasone 68Pemetrexed 64Bevacizumab 64Capecitabine 60atezolizumab 54fludarabine 49Azacitidine 49Fluorouracil 48130-nm albumin-bound paclitaxel 43venetoclax 41Trastuzumab 41Irinotecan 41Cetuximab 40Leucovorin 36Ipilimumab 36Erlotinib Hydrochloride 34Fulvestrant 32Cytarabine 32avelumab 31Oxaliplatin 31Albumin-Bound Paclitaxel 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × INDUSTRY × brivanib × Clear all
NCT04212221 2024-07-23

MGD013 Monotherapy and Combination With Brivanib Dose Escalation and Expansion Study in Advanced Liver Cancer Patients

Zai Lab (Hong Kong), Ltd.

Phase 1/2 Terminated
89 enrolled 23 charts
Gastrointestinal

Advanced Hepatocellular Carcinoma (HCC)

NCT01108705 2015-10-12

BRISK-APS

Bristol-Myers Squibb

Phase 3 Terminated
87 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT00300027 2010-03-02

Study of BMS-582664 in Combination With Either FOLFIRI or FOLFOX for Gastrointestinal (GI) Malignancies

Bristol-Myers Squibb

Phase 1 Terminated
50 enrolled
Gastrointestinal

Gastrointestinal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡